<DOC>
	<DOCNO>NCT01029704</DOCNO>
	<brief_summary>The purpose study assess effect EGT0001442 fasting plasma glucose 28 day treatment subject type 2 diabetes . The study also assess pharmacokinetics ( much drug get blood long take body get rid ) , safety tolerability EGT0001442 , effect weight HbA1c well effect EGT0001442 amount glucose produce body urine .</brief_summary>
	<brief_title>Safety Efficacy Study EGT0001442 Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female age 18 70 year diagnose type 2 diabetes . Body mass index ( BMI ) 18 kg/m2 37 kg/m2 ( inclusive ) . HbA1c level 6.5 9.5 ( inclusive ) upper limit normal HbA1c assay 6.4 % HbA1c level 6.2 9.5 % ( inclusive ) upper limit normal HbA1c assay 6.1 % . Fasting plasma glucose level 126 270 mg/dL ( 7 15 mmol/L , inclusive ) diabetic medication . Treatment na√Øve subject HbA1c 6.5 9.5 fasting plasma glucose 126 270 mg/dL ( 7 15 mmol/L ) . If take drug diabetes , must medically able willing discontinue diabetic medication duration study . Female subject must surgically sterilize postmenopausal . Type 1 diabetes diabetes treat insulin injection . Insulin therapy oral antidiabetic medication metformin , sitagliptin , saxagliptin , sulfonylurea combination . Sitting blood pressure 150/95 mmHg two evaluation least 10 minute apart screen . Positive result screen drug abuse . Previous treatment investigational drug within 30 day 7 halflives , whichever longer . Previous treatment EGT0001474 EGT0001442 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
</DOC>